Table 1.

Tumor features associated with cytoplasmic FGF2 expression assessed by IHC in an invasive breast cancer tissue microarray

FGF2 positiveFGF2 negativeP
Median tumor size (mm)20.5201a
Histologic grade
Vascular invasion75% (18/24)69% (120/175)0.64
Axillary node positive63% (16/24)67% (117/175)1
ER positive21% (5/24)86% (151/175)<0.0001
PR positive25% (6/24)77% (135/175)<0.0001
HER2 positive13% (3/24)13% (23/175)1
EGFR42% (10/24)5% (8/175)<0.0001
CK5/658% (14/24)5% (8/175)<0.0001
CK1446% (11/24)4% (7/175)<0.0001
Any basal marker79% (19/24)9% (15/175)<0.0001
Tumor subtype
 Core basal-like1610
 TN nonbasal09

Abbbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; CK5/6, cytokeratin 5/6; CK14, cytokeratin 14, any basal-marker (positive for any of EGFR, CK5/6 or CK14).

NOTE: Statistical analysis was with Fisher's exact test, unless indicated. Tumor subtype as defined by Nielsen and colleagues (ref. 28; HER2–HER2 amplified, Luminal–HER2 negative/ER positive, core basal-like–TN expressing CK5/6 or EGFR, TN nonbasal–TN with no expression of CK5/6 and EGFR).

  • aMann–Whitney U Test or

  • bχ2 test.